Recent insights into Immuno-Oncology
Cancer immunotherapy has recently become a crucial pillar of anticancer therapy. This is mainly because of the unmatched long-term responses elicited by immune checkpoint blockers and T cell-based therapies in patients with advanced cancer. In spite of this, the efficacy of these therapeutics is still limited to certain patients and cancer types, largely because of a variety of resistance mechanisms in tumors that are currently being identified. Understanding the dialogue between cancer cells and the immune system and the molecular mechanisms by which immune checkpoints regulate anti-tumor immunity are essential cornerstones for the improvement of cancer immunotherapy.
This upcoming conference brings together leaders with young investigators engaged in the fields of Immuno-Oncology, immunometabolism and cellular therapies, with the main scope of sharing new insights into the immune response to tumors and tackle unresolved questions.
We anticipate that the conference will provide a perfect forum to stimulate discussion and interaction among participants, clinicians and experts of the burgeoning and rapidly evolving field of Immuno-Oncology.
The program brings together world recognized experts who will present their recent work in sessions focused on:
- Cross talk myeloid cells
- Clinical or translational
- T Cell/ Immunotherapy
- Precision Immuno-Oncology
- Immune escape
Next to an inspiring scientific program, conference participants will have ample networking opportunities during the breaks, poster sessions and the conference dinner in a perfectly safe and stimulating environment.
Follow us on Twitter for the latest news.
Format: A0 (841 x 1189 mm / 33.1 x 46.8 in), portrait orientation.
- Travel Grant deadline: 24 March 2022
- Early Bird: 5 May 2022
- Late Registration: 2 June 2022
- Abstract deadline: 7 April 2022
Find out more here: Recent insights into Immuno-Oncology.
- Tobias Bald - Institute of Experimental Oncology, University Hospital Bonn, DE
- Nina Bhardwaj - The Tisch Cancer Institute, Icahn School of Medicine at Mt Sinai, US
- Hongbo Chi - St. Jude Children’s Research Hospital, US
- Michele De Palma - EPFL, CH
- Gianpetro Dotti - Lineberger Comprehensive Cancer Center / University of North Carolina at Chapel Hill, US
- Mikala Egeblad - CSHL, US
- Dmitry Gabrilovich - ICC, Early Oncology R&D, AstraZeneca, US
- Alena Gros - Vall d’Hebron Institute of Oncology (V.H.I.O.), Spain
- Ping-Chih Ho - University of Lausanne/Ludwig Institute for Cancer Research, CH
- Susan Kaech - "NOMIS Center for Immunobiology & Microbial Pathogenesis Salk Institute for Biological Studies, US"
- Lana Kandalaft - Department of Oncology, CHUV / UNIL & Ludwig Institute for Cancer Research, Lausanne Branch (LICR), CH
- Sergio Quezada - UCL, London, UK
- Caetano Reis e Sousa - Francis Crick Institute, UK
- Maria Rescigno - Humanitas University, IT
- Yardena Samuels - Department of Molecular Cell Biology, Weizmann Institute of Science, IL
- Andrea Schietinger - Memorial Sloan Kettering Cancer Center, US
- Daniela Thommen - The Netherlands Cancer Institute, NL
- Zlatko Trajanoski - Institute of Bioinformatics, Biocenter, Medical University of Innsbruck, AT
- Jo Van Ginderachter - VIB-UGent Center for Inflammation Research, BE